UA49955C2 - Водна фармацевтична композиція, що містить гемісульфат елетриптану і кофеїн - Google Patents
Водна фармацевтична композиція, що містить гемісульфат елетриптану і кофеїн Download PDFInfo
- Publication number
- UA49955C2 UA49955C2 UA99126573A UA99126573A UA49955C2 UA 49955 C2 UA49955 C2 UA 49955C2 UA 99126573 A UA99126573 A UA 99126573A UA 99126573 A UA99126573 A UA 99126573A UA 49955 C2 UA49955 C2 UA 49955C2
- Authority
- UA
- Ukraine
- Prior art keywords
- composition according
- volume
- mass
- amount
- ethanol
- Prior art date
Links
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 title claims abstract description 46
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 229960001948 caffeine Drugs 0.000 title claims abstract description 23
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 title abstract description 17
- 229960002472 eletriptan Drugs 0.000 title abstract description 17
- 239000000203 mixture Substances 0.000 claims description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 64
- IYVZCNNIKYUHHM-WXMGBDCWSA-N OS(O)(=O)=O.CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1.CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 Chemical compound OS(O)(=O)=O.CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1.CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 IYVZCNNIKYUHHM-WXMGBDCWSA-N 0.000 claims description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- 229960005070 ascorbic acid Drugs 0.000 claims description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims description 8
- 239000011668 ascorbic acid Substances 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000027559 Appetite disease Diseases 0.000 claims description 2
- 206010009094 Chronic paroxysmal hemicrania Diseases 0.000 claims description 2
- 206010013654 Drug abuse Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 208000007777 paroxysmal Hemicrania Diseases 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000003928 nasal cavity Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical group CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 150000002990 phenothiazines Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013097 stability assessment Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Packaging Of Annular Or Rod-Shaped Articles, Wearing Apparel, Cassettes, Or The Like (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9714081.8A GB9714081D0 (en) | 1997-07-03 | 1997-07-03 | Pharmaceutical compositions |
| GBGB9718270.3A GB9718270D0 (en) | 1997-07-03 | 1997-08-28 | Pharmaceutical compositions |
| PCT/EP1998/004176 WO1999001135A1 (en) | 1997-07-03 | 1998-07-01 | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA49955C2 true UA49955C2 (uk) | 2002-10-15 |
Family
ID=10815339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA99126573A UA49955C2 (uk) | 1997-07-03 | 1998-01-07 | Водна фармацевтична композиція, що містить гемісульфат елетриптану і кофеїн |
Country Status (13)
| Country | Link |
|---|---|
| KR (1) | KR100384346B1 (ko) |
| AP (1) | AP1100A (ko) |
| AR (1) | AR013165A1 (ko) |
| CO (1) | CO4950555A1 (ko) |
| GB (2) | GB9714081D0 (ko) |
| GT (1) | GT199800105A (ko) |
| HN (1) | HN1998000101A (ko) |
| MY (1) | MY119643A (ko) |
| PA (1) | PA8454501A1 (ko) |
| PE (1) | PE84499A1 (ko) |
| TN (1) | TNSN98126A1 (ko) |
| UA (1) | UA49955C2 (ko) |
| ZA (1) | ZA985812B (ko) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
-
1997
- 1997-07-03 GB GBGB9714081.8A patent/GB9714081D0/en active Pending
- 1997-08-28 GB GBGB9718270.3A patent/GB9718270D0/en active Pending
-
1998
- 1998-01-07 UA UA99126573A patent/UA49955C2/uk unknown
- 1998-06-30 MY MYPI98002961A patent/MY119643A/en unknown
- 1998-06-30 HN HN1998000101A patent/HN1998000101A/es unknown
- 1998-06-30 PE PE1998000581A patent/PE84499A1/es not_active Application Discontinuation
- 1998-07-01 AR ARP980103209A patent/AR013165A1/es unknown
- 1998-07-01 KR KR10-1999-7012523A patent/KR100384346B1/ko not_active IP Right Cessation
- 1998-07-01 TN TNTNSN98126A patent/TNSN98126A1/fr unknown
- 1998-07-01 PA PA19988454501A patent/PA8454501A1/es unknown
- 1998-07-02 AP APAP/P/1998/001290A patent/AP1100A/en active
- 1998-07-02 ZA ZA9805812A patent/ZA985812B/xx unknown
- 1998-07-03 CO CO98037816A patent/CO4950555A1/es unknown
- 1998-07-13 GT GT199800105A patent/GT199800105A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP1100A (en) | 2002-09-02 |
| GB9714081D0 (en) | 1997-09-10 |
| PE84499A1 (es) | 1999-09-11 |
| ZA985812B (en) | 2000-01-10 |
| GB9718270D0 (en) | 1997-11-05 |
| CO4950555A1 (es) | 2000-09-01 |
| MY119643A (en) | 2005-06-30 |
| KR20010014366A (ko) | 2001-02-26 |
| AR013165A1 (es) | 2000-12-13 |
| PA8454501A1 (es) | 2000-05-24 |
| KR100384346B1 (ko) | 2003-05-16 |
| HN1998000101A (es) | 1999-01-08 |
| GT199800105A (es) | 2000-01-04 |
| AP9801290A0 (en) | 1998-09-30 |
| TNSN98126A1 (fr) | 2005-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA002174B1 (ru) | Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин | |
| KR100345824B1 (ko) | 성적 장애를 치료하기 위한 비내용 제제 | |
| NL9102071A (nl) | Geneesmiddelen. | |
| US5169849A (en) | Nasal pharmaceutical compositions | |
| RU2255736C2 (ru) | Фармацевтические композиции, содержащие золмитриптан | |
| PL219338B1 (pl) | Preparat do podawania donosowego zawierający co najmniej jeden będący lekiem hormon płciowy wybrany spośród testosteronu, biologicznych proleków hormonu płciowego wybranych spośród androstendionu i progesteronu oraz ich połączeń, oraz dalsze składniki | |
| FI102873B (fi) | Menetelmä nitroglyseriinipitoisen, hydrofiilisen vesipitoisen pumpatta van sumutteen valmistamiseksi | |
| GB2162745A (en) | Nasal compositions | |
| UA49955C2 (uk) | Водна фармацевтична композиція, що містить гемісульфат елетриптану і кофеїн | |
| WO2017122161A1 (en) | An intranasal composition comprising 5ht1b/1d receptor agonists | |
| GB2114001A (en) | Nasal pharmaceutical compositions | |
| FI81258B (fi) | Foerfarande foer framstaellning av en farmaceutisk komposition foer nasal administration. | |
| TWI221769B (en) | Pharmaceutical compositions containing eletriptan hemisulphate | |
| ES2935684T3 (es) | Formulaciones de epinefrina intranasales y métodos para el tratamiento de enfermedades | |
| JP2002037735A (ja) | カフェイン類の安定化方法および粘膜適用組成物 | |
| HU226374B1 (en) | Pharmaceutical combination of a bradykinin antagonist and an antiviral agent | |
| MXPA99011299A (en) | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine | |
| CA3238583A1 (en) | Injectable and inhalable formulations | |
| CZ466099A3 (cs) | Farmaceutické kompozice obsahující elektriptanhemisulfat a kofein |